News Sentiment

CADL sentiment intelligence

Candel Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.49 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-3.5% over one week, +10.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -3.5% Price reacting lower
Trend fit Trend active 10.9% over four weeks
Fair value 83.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 37
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
Market source 8
TradingView 6
Investing.com 4
simplywall.st 4
Stocktwits 3
GlobeNewswire 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 11
Analyst action 5
Balance sheet 3
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
TradingView Direct company coverage

CADL Forecast — Price Target — Prediction for 2027

This article provides a forecast for Candel Therapeutics, Inc. (CADL) stock, including analyst price targets and future predictions. It details the company's financial performance, stock volatility, market capitalization, and upcoming earnings report, along with historical price

Tone
Positive 77/100
Event
Analyst action
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Candel Therapeutics, Inc. – BOATS:CADL

This article focuses on the enterprise value to revenue forward for Candel Therapeutics, Inc. (CADL) without providing specific financial figures. It appears to be a stub or a financial data page from TradingView. The content primarily consists of navigation, copyright informatio

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 15:10
Source
TradingView
Moomoo Direct company coverage

Press Release: Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics has announced the appointment of Mark Sims as its Chief Commercial Officer. Sims brings over 25 years of biopharmaceutical experience, including significant leadership roles at Amgen and Gilead, and is expected to drive the company's commercial strategy, parti

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 21:09
Source
Moomoo